MedTrace Logo

Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone

NCT07375654 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-01-29

No results posted yet for this study

Summary

This study is a comparative clinical study evaluating the efficacy of combined therapy using cyclosporine and metformin versus cyclosporine alone in the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that often requires systemic therapy in moderate to severe cases. Cyclosporine is an effective immunosuppressive agent; however, its long-term use is limited by potential adverse effects.

Metformin, a commonly used antidiabetic drug, has shown anti-inflammatory and immunomodulatory properties, which may enhance treatment outcomes in psoriasis. This study aims to assess whether adding metformin to cyclosporine improves clinical response compared to cyclosporine monotherapy.

Conditions

Interventions

DRUG

Cyclosporin (CSA)

Cyclosporine (dose 3 mg/kg),orally twice per day for 3 months

DRUG

Metformin (500 mg Twice a day)

Metformin (500 mg twice daily),orally for 3 months

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Marwa Salah El-Mesidy, Assistant Professor · Cairo University

  • Aya Mohamed Fahim, Assistant Professor · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-19
Primary Completion
2025-10-04
Completion
2025-11-04

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07375654 on ClinicalTrials.gov